We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Predictors of Treatment Outcome for Smokers With and Without Schizophrenia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00501007
First Posted: July 13, 2007
Last Update Posted: July 17, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Marc L. Steinberg, Ph.D., Rutgers, The State University of New Jersey
  Purpose
The primary purpose of this investigation is to determine the predictive value of task persistence as measured by a mirror tracing task. A secondary purpose is to evaluate differences in task persistence in smokers with or without schizophrenia. It is hypothesized that task persistence in smokers in both diagnostic categories (schizophrenia and no schizophrenia) will predict tobacco dependence treatment outcome at one and six months. It is also hypothesized that smokers with schizophrenia will show lower levels of task persistence after controlling for other motor skills than smokers without schizophrenia.

Condition
Tobacco Dependence

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Predictors of Treatment Outcome for Smokers With and Without Schizophrenia

Resource links provided by NLM:


Further study details as provided by Marc L. Steinberg, Ph.D., Rutgers, The State University of New Jersey:

Primary Outcome Measures:
  • Mirror-tracing Persistence (in Seconds) [ Time Frame: baseline ]
    Number of seconds participants continued working on a mirror tracing task before giving up.


Secondary Outcome Measures:
  • Persistence as a Prospective Predictor of Smoking Cessation [ Time Frame: 6 months ]
    Analysis of Generalized Estimating Equations (GEE) parameter estimates based on empirical standard error estimates, using an exchangeable working correlation structure, with smoking abstinence as outcome variable, and task persistence, time, diagnosis, ability, Fagerstrom Test for Nicotine Dependence (FTND) score, and the interaction between disorder and persistence as explanatory variables.


Enrollment: 203
Study Start Date: February 2005
Study Completion Date: January 2013
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Non-psychiatric smokers
Smokers not meeting criteria for Schizophrenia or Schizoaffective Disorder
Smokers with Schizophrenia
Smokers meeting criteria for schizophrenia or schizoaffective disorder

Detailed Description:
Please see brief summary above.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Individuals from mental health centers in Central New Jersey or non-psychiatric controls from the community
Criteria

Inclusion Criteria:

  • Current smokers must be over the age of 18,
  • Must fit into the diagnostic groups schizophrenia / schizoaffective disorder; or the non-schizophrenia group.
  • Must smoke at least 10 cigarettes per day
  • Must be capable of giving informed consent as measured by Folstein Mini Mental Status Exam of at least 22.

Exclusion Criteria:

  • Those unable to give informed consent.
  • Psychotic disorders other than schizophrenia
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00501007


Locations
United States, New Jersey
UMDNJ Tobacco Dependence Clinic
New Brunswick, New Jersey, United States, 08901
Sponsors and Collaborators
Rutgers, The State University of New Jersey
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Marc L. Steinberg, PH.D Rutgers, The State University of New Jersey
  More Information

Responsible Party: Marc L. Steinberg, Ph.D., Associate Professor, Rutgers, The State University of New Jersey
ClinicalTrials.gov Identifier: NCT00501007     History of Changes
Other Study ID Numbers: K23DA018203 ( U.S. NIH Grant/Contract )
First Submitted: July 11, 2007
First Posted: July 13, 2007
Results First Submitted: January 7, 2013
Results First Posted: December 13, 2013
Last Update Posted: July 17, 2017
Last Verified: July 2017

Additional relevant MeSH terms:
Schizophrenia
Tobacco Use Disorder
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Substance-Related Disorders
Chemically-Induced Disorders